Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

Leuk Res. 2004 Jul;28(7):707-11. doi: 10.1016/j.leukres.2003.11.009.

Abstract

We measured telomerase activity (TA) in bone marrow samples from 214 patients with CLL and correlated it with patients' characteristics and survival. In >50% of cases (126/214; 59%) no detectable TA was found. There was no difference in TA between previously treated (n = 153) and untreated (n = 61) patients (P = 0.4), or patients with various Rai (0-IV) stages (P = 0.85). TA correlated significantly with white blood cell and lymphocyte count (P = 0.02 and 0.01, respectively) but not with bone marrow cellularity, beta2-microglobulin (beta2M), or other patient characteristics. Patients who had no TA had slightly lower beta2M and lower lymphocyte counts (P = 0.5 and 0.04, respectively) as compared with patients with detectable TA. However, there was no correlation between TA and survival. This data suggests that TA may not play a significant role in the clinical behavior of CLL.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / pharmacology
  • Bone Marrow Cells
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukocyte Count
  • Lymphocyte Count
  • Middle Aged
  • Neoplasm Staging
  • Polymerase Chain Reaction
  • Prognosis
  • Telomerase / analysis
  • Telomerase / metabolism*
  • beta 2-Microglobulin / analysis

Substances

  • Antineoplastic Agents
  • beta 2-Microglobulin
  • Telomerase